Use access key #2 to skip to page content.
$8.04 -0.36 (-4.29%)
10/10/2008 4:00 PM

CV Therapeutics, Inc. (CVTX)

CAPS Rating:
***

A biopharmaceutical company focused on the discovery, development and commercialization of new small molecule drugs for the treatment of cardiovascular diseases.

View All Commentary (CVTX)

Recs

3

Avatar Sayder (< 20) Submitted: 3/19/08 11:25 PM : Outperform Start Price: $5.88 CVTX Score: 69.81

Current FDA approval for Regadenoson should be coming within a few months, as well as the improved rating approval for Ranexa later around the July-October time frame. Additionally, institutional ownership is greater than 100% of total shares outstanding (several people are currently shorting the stock). Just one piece of good news could send this stock up if the institutions hold onto their shares. With a shortage of shares on the market, the share price should really move as the others try to cover their shorts. However, without FDA approval of their drugs (and soon), they probably won't survive 2 more years.

Report this Post Replies: 0 | Reply

Featured Broker Partners